Mapping Out Oncology Development: Filling Gaps and Avoiding Pitfalls

Nine out of 10 clinical trials for new drugs fail; Oncology drugs have a 3.4 percent probability of succeeding. Still, cancer drugs can and are being commercialized. From 2003 to 2020, 124 oncology therapies were approved by FDA. What makes this possible? Knowing the key factors to consider at each juncture of development is critical to build the right roadmap for your product. In this webinar, you will learn how examining each step of drug development helps sponsors find success for cancer therapies. Topics include:

    • How to fill gaps and avoid pitfalls of oncology drug development
    • The importance of early phase planning, from optimum dosage to formulation
    • The role of end-of-phase planning, such as regulatory feedback